Poly-thyronine

Poly-Thyronine: A Reference Entry

Preliminary Note on Identity and Evidential Status

"Poly-thyronine" is a term encountered primarily in the dietary supplement industry and in a discrete body of pharmaceutical patent literature from the late 20th century. It does not correspond to a single, universally agreed-upon chemical entity, and it is absent from the monographs of major authoritative bodies including the World Health Organization, the European Medicines Agency, the National Institutes of Health Office of Dietary Supplements, the European Scientific Cooperative on Phytotherapy (ESCOP), and the German Commission E. No peer-reviewed systematic review, meta-analysis, or registered clinical trial specifically investigating "poly-thyronine" as a named dietary supplement could be located in the PubMed/PMC database as of the date of this article. Sources that do use the term range from incongruent supplement marketing descriptions to U.S. patent filings describing experimental drug-delivery polymers. These facts are stated explicitly at the outset because an honest characterization of this ingredient requires acknowledging the severe limitations of the available record. The sections below document only what authoritative or peer-reviewed sources actually state.

Identity and Chemical Description

The "Thyronine" Nucleus

The thyroid hormones are α-amino acid derivatives of tyrosine. The thyronine nucleus consists of two benzene rings in ether linkage, with an alanine side chain in the para position on the inner or tyrosyl ring and a hydroxyl group in the para position in the outer or phenolic ring. Thyroxine was the first thyroid hormone to be isolated and characterized; its name derives from "thyroid oxyindole," which describes the chemical structure erroneously assigned to it when it was initially isolated in 1914. Triiodothyronine, a considerably less abundant but far more potent hormone than thyroxine in most assay systems, was not discovered until 1953. Both hormone molecules are exceptionally rich in iodine, which comprises more than half of their molecular weight. Thyroxine contains four atoms of iodine and is abbreviated as T4; triiodothyronine, which has three atoms of iodine, is abbreviated as T3.

Poly-Thyronine in Patent Literature: Iodothyronine Polymers

The most precise and verifiable use of the concept of "poly-thyronine" in a scientific or technical context appears in U.S. and international patent literature from the late 1980s through the 1990s. These patents describe iodothyronine polymers having a plurality of recurring units of a defined chemical formula in which iodo substituents vary; polymers in which specific positions are iodo and in which substantially all of the recurring units are L-stereoisomers are described as having utility in treating thyroid hormone deficiencies.

The iodothyronine polymers described in these patents are intended to provide a method of delivering thyroid hormones to a patient in need thereof. Because the thyroid hormones are released by digestive proteolysis of the iodothyronine polymers, it was expected that their use would have a long physiologic effect because of sustained release of the monomeric thyroid hormones from the polymers.

The use of copolymers containing recurring units derived from two or more thyroid hormones, or mixtures of homopolymers of the thyroid hormones in the appropriate ratio, was proposed as a means whereby the naturally occurring ratio of thyroid hormones might be duplicated.

Specific polymeric forms described in this patent literature include: polymeric 3,5,5'-triiodo-L-thyronine (poly-rLT3); a polymer containing recurring units derived from both L-thyroxine (LT4) and triiodo-L-thyronine (LT3) (poly-LT4/LT3); and polymeric 3,5-diiodo-L-thyronine (poly-3,5-LT2). The average chain length of the polymer was specified: the average number of recurring units may vary from about 5 to about 400, preferably from about 10 to about 400, more preferably from about 20 to about 200, or from about 30 to about 150, or from about 80 to about 120.

These iodothyronine polymers were proposed for use in the treatment of thyroid disorders. Since these polymers are released by digestive proteolysis, it was expected that they would have a long physiologic effect because of the sustained release from the polymers of the monomeric thyroid hormones, thus giving stable, consistent pharmaceutical compositions for the treatment of thyroid hormone deficiencies.

It must be noted that these patent descriptions are for investigational pharmaceutical compositions. No approved drug product based on these iodothyronine polymers is identified in authoritative databases, and no clinical trials of such polymer formulations in human subjects were located.

How the Term Is Used in the Supplement Industry

Within the dietary supplement industry, the term "poly-thyronine" appears as an ingredient listing in several thermogenic and weight-management products. The descriptions given by supplement-adjacent sources are internally inconsistent. One source states it "may help increase your metabolic rate" in the context of a fat-burning blend alongside guggulsterones, L-carnitine, and alpha lipoic acid. Other sources describe poly-thyronine as a term that generally refers to synthetic forms of thyroid hormones, such as liothyronine (T3) or combinations of T3 and T4. Still others describe it as a combination product of vitamins, minerals, and herbs. These contradictory descriptions reflect a lack of standardized identity for this ingredient, and none are supported by authoritative monographs or peer-reviewed biochemical characterization.

Relationship to 3,5-Diiodo-L-Thyronine (T2): The Closest Peer-Reviewed Analogue

The dietary supplement ingredient with the strongest scientific literature that is structurally related to "poly-thyronine" is 3,5-diiodo-L-thyronine (3,5-T2). This is a distinct, specific compound — not "poly-thyronine" itself — but it appears both in patent-described polymer forms and in supplements marketed similarly. Given the well-known metabolic effects of thyroid hormones, it is not surprising that a thyroid hormone metabolite, 3,5-diiodo-L-thyronine (T2), has found its way into the formulations of a number of dietary supplements that claim to decrease body fat.

Over 30 years of research has demonstrated that 3,5-diiodo-L-thyronine (3,5-T2), an endogenous metabolite of thyroid hormones, exhibits interesting metabolic activities. In rodent models, exogenously administered 3,5-T2 rapidly increases resting metabolic rate and elicits short-term beneficial hypolipidemic effects; however, very few studies have evaluated the effects of endogenous and exogenous T2 in humans.

Traditionally, thyroxine (T4) and triiodo-L-thyronine (T3) were the only thyroid hormones considered to have metabolic effects. Several observations, however, led to a reconsideration of this idea. In recent years, studies dealing with the biological activities of some natural metabolites or structural analogues of thyroid hormones have revealed abilities to ameliorate some major worldwide medical problems such as atherosclerosis, obesity, and cardiovascular diseases. Among natural metabolites, 3,5-diiodothyronine (T2) has been shown to powerfully reduce adiposity and dyslipidaemia and to reverse hepatic steatosis without unfavorable side effects usually observed when T3 or T4 is used.

Natural Sources and Occurrence

Thyronine-based hormones and their metabolites — including those forming the basis of "poly-thyronine" preparations — are endogenous compounds produced by the mammalian thyroid gland. They are not derived from plants in any pharmacologically meaningful concentration. Plants such as Ascophyllum nodosum (sea kelp) and Fucus vesiculosus (bladderwrack) are common ingredients of thyroid-support supplement products, as they are known as natural sources of dietary iodine — a precursor nutrient required for thyroid hormone biosynthesis, but distinct from thyronine polymers themselves.

Animal-derived thyroid gland extracts (desiccated thyroid, most often from porcine or bovine sources) contain the full range of thyroid hormones including T4, T3, T2, and their metabolites. Due to their complex biological origin, these medications contain many compounds that are uncharacterized for safety and effectiveness. The poly-thyronine concept in patents envisions a synthetic polymerization of iodothyronine amino acid monomers rather than extraction from a natural source.

Traditional and Historical Use

No traditional use of "poly-thyronine" as a named substance has been documented in historical pharmacopoeias, ethnobotanical records, or well-characterized ethnopharmacological literature, because the compound as a synthetic polymer was conceived in late-20th-century pharmaceutical research contexts. The historical use of thyroid-related preparations is instead documented for desiccated animal thyroid glands, which have been used in conventional medicine since the late 19th century as treatments for hypothyroidism. This is a distinct category from any supplement ingredient labeled "poly-thyronine."

Claims found in supplement-industry-adjacent sources — that "herbalists in various cultures recognized its potential" or that poly-thyronine "traces back to holistic and traditional medicinal practices" — are not substantiated by any identified historical pharmacopoeial record, ethnobotanical database, or peer-reviewed historical study of traditional medicine. These claims are therefore omitted as unverifiable.

Mechanisms of Action

Because "poly-thyronine" has no standardized identity, a definitive mechanism of action cannot be stated. The mechanisms described in the patent literature for iodothyronine polymers are those of the monomeric thyroid hormones released after proteolytic digestion. For the related compound 3,5-T2, the following has been established in research:

Several lines of evidence suggest that 3,5-T2 mainly acts through thyroid hormone receptor (THR)-independent ways, with mitochondria as a likely cellular target, though THR-mediated actions have also been described. The detailed cellular and molecular mechanisms through which 3,5-T2 elicits a multiplicity of actions remain unknown.

Mode of administration (oral, intraperitoneal, subcutaneous), duration and dose of 3,5-T2, possible contamination by T3, age and strain differences of rodent models used, as well as distinct composition of diets offered might affect different outcomes of experiments. Several reports present clear evidence for thyroid hormone receptor-mediated action of 3,5-T2 on expression of T3-responsive genes in several tissues, in addition to rapid plasma membrane, cytosolic signal, and mitochondrial effects.

For the broader category of thyroid hormone-related compounds, the mechanism relevant to cholesterol management has been described: Hypothyroidism is associated with elevated cholesterol levels, especially LDL cholesterol, due to reduced LDL receptor activity in the liver. Thyroid hormone replacement therapy restores normal thyroid function, which in turn lowers serum cholesterol levels by increasing hepatic LDL receptor expression and enhancing cholesterol clearance.

The German Centre for Cardiovascular Research identifies 3,5-diiodothyronine (3,5-T2) as demonstrating anti-steatotic hepatic effects in rodent models and early human trials through non-canonical mitochondrial mechanisms — potentially complementing conventional hormone replacement rather than replacing it.

Scientific Evidence by Area of Use

Important Framing Note

No peer-reviewed clinical studies specifically testing a product labeled "poly-thyronine" in human subjects were identified. The evidence summarized below pertains to the closely related compound 3,5-T2 and to thyroid hormone polymer concepts from patent-stage research. Evidence strength is characterized explicitly for each area.

Metabolic Rate and Body Weight

Evidence strength: Preclinical (animal); one very small human case report only. Insufficient for conclusions about efficacy or safety in humans.

In rodent models, exogenously administered 3,5-T2 rapidly increases resting metabolic rate and elicits short-term beneficial hypolipidemic effects; however, very few studies have evaluated the effects of endogenous and exogenous T2 in humans.

A case report involving two participants revealed that administration of 3,5-T2 to humans (1–5 μg/kg body weight) rapidly (after 4–6 hours) increased resting metabolic rate. Chronic 3,5-T2 administration (28 days, approximately 5 μg/kg body weight) increased resting metabolic rate by approximately 15% and decreased body weight by approximately 4 kg in both participants. Principal clinical parameters showed no significant changes and no side effects such as cardiac abnormalities were observed.

Reliable quantification methods to measure endogenous levels of 3,5-T2 have been lacking, and the data reported so far need independent analytical confirmation.

Although the ability of T2 to increase metabolism is not in doubt, it is not evident from published studies what conditions allow for its safe and effective use in humans. This is due in part to the lack of comprehensive human studies, but it is also the result of the fragmented information available in the literature. Published studies often focus on different biochemical or physiological endpoints while using different experimental designs, models, and T2 doses.

Lipid Metabolism and Hepatic Steatosis

Evidence strength: Preclinical (animal, primarily rodent). Human data are absent or very sparse.

Simultaneous 3,5-T2 administration (25 μg/100 g body weight) for 4 weeks to rats feeding a high-fat diet prevents fatty liver and increases in body weight by increasing fatty acid oxidation rate and mitochondrial uncoupling to burn fat. Reductions in serum triglycerides and cholesterol levels, as well as improved insulin sensitivity, are also associated with 3,5-T2 administration in these animal models.

Accumulating evidence has indicated that 3,5-T2 can increase the metabolic rate and prevent high-fat diet-induced obesity. Administration of T2 counteracted the occurrence of metabolic disorders associated with high-fat feeding in rodent models.

In numerous studies based predominantly on rodent models, administration of 3,5-T2 was reported to cause beneficial health effects, including reversal of steatohepatosis and prevention of insulin resistance, in most instances without adverse thyrotoxic side effects. However, the empirical evidence concerning the physiological relevance of endogenously produced 3,5-T2 in humans is comparatively poor.

Browning of Adipose Tissue

Evidence strength: Animal only. No human evidence identified.

The conversion of white adipose cells into beige adipose cells is known as browning, a process affecting energy metabolism. It has been shown that 3,5-diiodo-L-thyronine (T2), an endogenous metabolite of thyroid hormones, stimulates energy expenditure and a reduction in fat mass in animal models.

Considering the many metabolic activities shown by T2 and that at the lowest dose used it is not associated with thyrotoxicity or undesirable cardiovascular side effects in animal experiments, new evidence of how this diiodothyronine affects energy expenditure may be useful to stimulate investigation on its potential use as an antilipidemic agent.

Thyroid Hormone Deficiency (Polymer Drug Delivery Concept)

Evidence strength: Animal only (one in-vivo experiment in rats described in patent literature). No human clinical trial identified.

In one patent-described animal experiment, a treatment group of six rats received 10 μg/day of an iodothyronine polymer (poly-T4/T3) slurried in corn syrup orally by gavage. After 8 days of treatment, serum levels of LT3 and LT4 were measured by radioimmunoassay. The patent document concluded that these data demonstrated that oral administration of the copolymer of LT4 and LT3 can treat thyroid hormone deficiencies resulting from insufficient thyroidal release of thyroid hormones. This conclusion is based solely on an experiment in six rats and has not been validated in human clinical trials.

Cholesterol Management

Evidence strength: Clinical evidence exists for thyroid hormone replacement in hypothyroid patients, but this is for approved pharmaceutical thyroid hormone replacement — not for poly-thyronine supplements.

There is scientific evidence supporting the use of thyroid hormones in the management of cholesterol, particularly in individuals with hypothyroidism. Hypothyroidism is associated with elevated cholesterol levels, especially LDL cholesterol, due to reduced LDL receptor activity in the liver. Thyroid hormone replacement therapy (using levothyroxine or liothyronine) restores normal thyroid function, which in turn lowers serum cholesterol levels by increasing hepatic LDL receptor expression and enhancing cholesterol clearance. This evidence applies to approved, standardized pharmaceutical drugs and cannot be extrapolated to a supplement ingredient of uncertain identity and composition.

Dosage Forms

Because "poly-thyronine" is not a standardized, pharmacopoeially-defined ingredient, no validated dosing regimen exists. The following observations are drawn directly from the sources located and are presented only as descriptions of what has been reported, not as recommendations.

• In the only identified human case report pertaining to the related compound 3,5-T2: administration of 3,5-T2 to two participants at 1–5 μg/kg body weight rapidly increased resting metabolic rate. Chronic administration over 28 days at approximately 5 μg/kg body weight increased resting metabolic rate by approximately 15% and decreased body weight by approximately 4 kg in both participants.
• In the patent-described animal study of iodothyronine polymers: a treatment group of six rats received 10 μg/day of the iodothyronine polymer slurried in corn syrup orally by gavage.
• The polymer chain length in the pharmaceutical patent specifications was described as: an average number of recurring units varying from about 5 to about 400, preferably from about 10 to about 400, more preferably from about 20 to about 200, or from about 30 to about 150, or from about 80 to about 120.

No validated human clinical dosing range for any product specifically identified as "poly-thyronine" exists in the peer-reviewed literature.

Body Systems and Health Areas of Association

Based on its structural relationship to thyroid hormone-derived compounds and the claims made for it in supplement contexts, poly-thyronine is associated with the following body systems and health areas. The strength of evidence for each is noted:

• Endocrine system / thyroid axis: Thyronine-based compounds act on or through thyroid hormone receptors and modulate the hypothalamus-pituitary-thyroid (HPT) axis. Administration of 3,5-diiodothyronine causes central hypothyroidism and stimulates thyroid-sensitive tissues. (Animal evidence; human relevance unknown.)
• Metabolic rate and energy expenditure: In rodent models, exogenously administered 3,5-T2 rapidly increases resting metabolic rate. (Animal evidence; very limited human case report data.)
• Lipid metabolism: Among natural thyroid hormone metabolites, 3,5-diiodothyronine (T2) has been shown to powerfully reduce adiposity and dyslipidaemia and to reverse hepatic steatosis without unfavorable side effects usually observed when T3 or T4 is used — in animal models. (Animal evidence; human evidence very sparse.)
• Body composition: Fat mass reduction and prevention of diet-induced obesity have been observed in rodent studies of T2. (Animal evidence only.)
• Cardiovascular risk markers: Reduction in serum triglycerides and cholesterol has been observed in animal models. There is a considerable bias in the literature towards the beneficial effects of T2, leaving its potential deleterious consequences insufficiently explored. If thyromimetic effects may extend to many organs, there is a significant possibility that T2 administration may result in long-term undesirable effects.

Safety Considerations and Interactions

Safety information for "poly-thyronine" as a named supplement ingredient is not available from any identified authoritative source. The following safety information pertains to thyroid hormone-containing dietary supplements broadly and to the related compounds for which documented evidence exists.

Regulatory Status

The FDA has warned the public about safety concerns with unapproved animal-derived thyroid medications for patients with hypothyroidism. Current treatment options for hypothyroidism include synthetic medications containing levothyroxine or liothyronine (or a combination of both) and animal-derived thyroid medications; while synthetic thyroid medications are approved by the FDA, animal-derived thyroid medications are not and have not been reviewed for safety, purity, and potency.

FDA is aware of over 500 adverse event reports associated with animal-derived thyroid products from 1968 through February 2025, with a substantial increase between 2019–2020 that may have been related to several voluntary recalls of subpotent or superpotent products.

Risk of Thyrotoxicosis from Thyroid-Containing Supplements

Commercially available thyroid supplements can contain clinically relevant amounts of triiodothyronine, and consumption has the potential to cause profound metabolic derangements. The fact that these products are readily available on the internet market, often without online disclosure of the active ingredients, poses a substantial health risk.

A case of acute thyrotoxicosis was documented in the CDC's Morbidity and Mortality Weekly Report (MMWR) following consumption of an internet-purchased dietary supplement: Thyroid function studies indicated TSH <0.01 mIU/mL (normal range 0.27–4.20 mIU/mL), T3 >32.5 pg/mL (normal range 1.80–4.60 pg/mL), and T4 >7.8 ng/dL (normal range 0.9–1.8 ng/dL). The active ingredient listed on the bottle of diet pills was "triiodothyronine hormone 25 mcg." The patient was admitted to the hospital with a diagnosis of acute thyrotoxicosis, secondary to exogenous thyroid hormone.

Thyrotoxicosis as a Documented Adverse Event Pattern

In a survey-based adverse event reporting study of thyroid hormone extract use by physicians from the American Thyroid Association, the Endocrine Society, and the American Association of Clinical Endocrinologists, 62 (68%) of analyzed subjects had developed new symptoms associated with altered thyroid-stimulating hormone. A majority of TSH changes and symptoms described were consistent with thyrotoxicosis (65%), and 2 patients had developed arrhythmias. Reporters noted difficulty in dose adjustment by primary care providers due to confusion in interpreting thyroid function test results.

Potential for HPT Axis Suppression

More recent animal studies challenged an optimistic view by demonstrating adverse consequences of dose-dependent 3,5-T2 treatment such as an increased heart weight and suppression of the HPT axis. This confirmed the results of earlier in vivo studies in rats that indicated differential liver-stimulating and thyrotropin (TSH)-suppressing thyromimetic effects of 3,5-T2 compared with T3.

Inconsistency of Hormone Levels in Non-Standardized Products

The FDA has received complaints and reports of adverse events related to the safety and strength of animal-derived thyroid medications. The manufacturing process may result in tablets with inconsistent thyroid hormone levels within the same batch, leading to patients being either under- or over-treated.

Known Adverse Effects of Thyroid Hormone Excess

Adverse reactions consistent with thyroid hormone overdose include arrhythmias, myocardial infarction, dyspnea, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.

Interactions

Multiple drugs are known to affect thyroid hormone pharmacokinetics and metabolism — including absorption, synthesis, secretion, catabolism, protein binding, and target tissue response — and may alter the therapeutic response to thyroid hormone preparations. This is particularly relevant if a supplement ingredient such as poly-thyronine contains biologically active thyroid hormone moieties, as such interactions could affect the management of any co-administered thyroid drug.

Summary of Evidence Strength

For "poly-thyronine" specifically: no human clinical trials, no peer-reviewed mechanistic studies, no government-recognized safety profile, and no pharmacopoeial monograph exist. The term refers inconsistently in supplement contexts to either an incompletely defined hormonal ingredient or a class of experimental pharmaceutical polymers described only in patent filings.

For the closest scientifically-characterized analogue (3,5-T2): further analyses on larger cohorts are needed to determine whether 3,5-T2 is a potent additional modulator of energy metabolism. Data on 3,5-T2 in humans are generally sparse, and the existing animal findings cannot be reliably extrapolated to human use without further clinical investigation. There is a considerable bias in the literature towards the beneficial effects of T2, leaving its potential deleterious consequences insufficiently explored. If we consider that its thyromimetic effects may extend to many organs, there is a significant possibility that T2 administration may result in long-term undesirable effects.

References

• US Patent 5767227A — Iodothyronine Polymers (Google Patents)
• WO1991006569A1 — Iodothyronine Polymers (Google Patents / WIPO)
• Thyronine — An Overview (ScienceDirect Topics)
• 3,5-Diiodothyronine: A Novel Thyroid Hormone Metabolite and Potent Modulator of Energy Metabolism — Frontiers in Endocrinology / PMC (2018)
• 3,5-Diiodo-L-Thyronine (T2) in Dietary Supplements: What Are the Physiological Effects? — Endocrinology / PMC (2015)
• 3,5-Diiodo-L-Thyronine (3,5-T2) Exerts Thyromimetic Effects on Hypothalamus-Pituitary-Thyroid Axis, Body Composition, and Energy Metabolism in Male Diet-Induced Obese Mice — PMC (2015)
• 3,5 Diiodo-l-Thyronine (T2) Promotes the Browning of White Adipose Tissue in High-Fat Diet-Induced Overweight Male Rats — PMC (2019)
• A Thyroid Hormone-Independent Molecular Fingerprint of 3,5-Diiodothyronine Suggests a Strong Relationship with Coffee Metabolism in Humans — PMC (2019)
• Thyrotoxicosis After Consumption of Dietary Supplements Purchased Through the Internet — CDC MMWR (2016)
• FDA's Actions to Address Unapproved Thyroid Medications — U.S. Food and Drug Administration (2025)
• Animal-Derived Thyroid Products: Notice to Industry — U.S. FDA (August 2025)
• Adverse Event Reporting in Patients Treated with Thyroid Hormone Extract — Endocrine Practice (2017)
• FDA Cracks Down on Unapproved Animal-Derived Thyroid Medications — Clinical Advisor (2025)
• US Patent 5910569 — Iodothyronine Polymers (USPTO)
• Relationship: Cholesterol (High) and Poly-Thyronine — Caring Sunshine (supplement reference database)